Gambaran Umum
Genmab A/S, headquartered in Copenhagen, Denmark, operates as a leading biotechnology company focusing primarily on the creation of antibody therapeutics for the treatment of cancer. It is renowned for its innovative approach to antibody technology, particularly through its proprietary platforms such as DuoBody® for dual targeting and HexaBody® for enhanced effector function. A key project includes the development of Daratumumab, an antibody marketed as Darzalex, used in multiple myeloma treatments, which exemplifies Genmab’s capabilities in transforming scientific research into successful therapeutic solutions. The company's dedication to addressing complex medical challenges and its collaborations with major pharmaceutical firms underscore its pivotal role in advancing oncology treatment.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Genmab A/S - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 3,646.88 MM.
- Nilai operating income untuk Genmab A/S - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 1,274.46 MM.
- Nilai net income untuk Genmab A/S - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 1,370.90 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 3,646.88 | 1,274.46 | 1,370.90 |
| 2025-03-31 | 3,230.90 | 1,097.68 | 1,139.52 |
| 2024-12-31 | 21,526.00 | 7,079.00 | 7,844.00 |
| 2024-09-30 | 19,844.00 | 6,563.00 | 4,702.00 |
| 2024-06-30 | 2,742.74 | 881.66 | 798.29 |
| 2024-03-31 | 2,575.77 | 825.27 | 791.06 |
| 2023-12-31 | 16,474.00 | 5,321.00 | 4,352.00 |
| 2023-09-30 | 16,852.00 | 6,183.00 | 4,163.00 |
| 2023-06-30 | 16,227.00 | 6,429.00 | 4,641.00 |
| 2023-03-31 | 15,220.00 | 6,208.00 | 5,197.00 |
| 2022-12-31 | 14,505.00 | 6,267.00 | 5,452.00 |
| 2022-09-30 | 11,987.00 | 4,501.00 | 5,654.00 |
| 2022-06-30 | 10,210.00 | 3,460.00 | 3,962.00 |
| 2022-03-31 | 9,020.00 | 3,000.00 | 2,377.00 |
| 2021-12-31 | 8,417.00 | 2,953.00 | 2,957.00 |
| 2021-09-30 | 7,907.00 | 3,118.00 | 2,873.00 |
| 2021-06-30 | 7,321.00 | 3,086.00 | 2,513.00 |
| 2021-03-31 | 10,800.00 | 6,796.00 | 5,585.00 |
| 2020-12-31 | 10,111.00 | 6,313.00 | 4,758.00 |
| 2020-09-30 | 11,028.00 | 7,602.00 | 5,649.00 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Genmab A/S - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 21.72.
- laba per saham yang terdilusi untuk Genmab A/S - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 21.62.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | 21.72 | 21.62 |
| 2025-03-31 | 18.37 | 18.36 |
| 2024-12-31 | 122.21 | 121.36 |
| 2024-09-30 | 72.74 | 72.21 |
| 2024-06-30 | 12.26 | 12.17 |
| 2024-03-31 | 4.91 | 4.87 |
| 2023-12-31 | 66.64 | 66.02 |
| 2023-09-30 | 63.76 | 63.15 |
| 2023-06-30 | 71.09 | 70.35 |
| 2023-03-31 | 79.50 | 78.76 |
| 2022-12-31 | 83.38 | 82.59 |
| 2022-09-30 | 86.43 | 85.63 |
| 2022-06-30 | 60.54 | 59.98 |
| 2022-03-31 | 36.33 | 35.99 |
| 2021-12-31 | 45.22 | 44.77 |
| 2021-09-30 | 43.93 | 43.50 |
| 2021-06-30 | 38.45 | 38.05 |
| 2021-03-31 | 85.60 | 84.69 |
| 2020-12-31 | 73.00 | 72.21 |
| 2020-09-30 | 86.82 | 85.83 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Genmab A/S - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 1,134.40 MM.
- Nilai cash from investing activities untuk Genmab A/S - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -96.68 MM.
- Nilai kas dari aktivitas pendanaan untuk Genmab A/S - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -510.98 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | 1,134.40 | -96.68 | -510.98 |
| 2025-03-31 | 1,193.94 | -1,268.43 | -495.82 |
| 2024-12-31 | 7,771.00 | -9,907.00 | -3,919.00 |
| 2024-09-30 | 6,731.00 | -10,431.00 | -3,944.00 |
| 2024-06-30 | 970.89 | -1,398.68 | -525.29 |
| 2024-03-31 | 818.50 | -393.54 | -84.28 |
| 2023-12-31 | 7,380.00 | -1,282.00 | -606.00 |
| 2023-09-30 | 6,106.00 | -976.00 | -453.00 |
| 2023-06-30 | 6,037.00 | -3,366.00 | -1,115.00 |
| 2023-03-31 | 6,560.00 | -2,107.00 | -1,336.00 |
| 2022-12-31 | 3,912.00 | -2,761.00 | -789.00 |
| 2022-09-30 | 3,755.00 | -2,931.00 | -904.00 |
| 2022-06-30 | 2,234.00 | -3,170.00 | -238.00 |
| 2022-03-31 | 1,630.00 | -1,049.00 | -264.00 |
| 2021-12-31 | 2,228.00 | -961.00 | -420.00 |
| 2021-09-30 | 1,189.00 | -1,369.00 | -403.00 |
| 2021-06-30 | 5,820.00 | -2,313.00 | -408.00 |
| 2021-03-31 | 5,704.00 | -2,939.00 | -164.00 |
| 2020-12-31 | 6,433.00 | -2,351.00 | 71.00 |
| 2020-09-30 | 7,406.00 | -2,788.00 | 46.00 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 | ||
| 2020-09-30 |
Efektivitas Manajemen
- roa untuk Genmab A/S - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.03.
- roe untuk Genmab A/S - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.04.
- roic untuk Genmab A/S - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.21.
- croic untuk Genmab A/S - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.08.
- ocroic untuk Genmab A/S - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.22.
| Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
| 2025-06-30 | 0.03 | 0.04 | 0.21 | -0.08 | 0.22 |
| 2025-03-31 | 0.21 | 0.24 | 0.21 | -0.13 | 0.21 |
| 2024-12-31 | 0.13 | 0.15 | 0.14 | -0.24 | 0.20 |
| 2024-09-30 | 0.16 | 0.18 | 0.17 | -0.20 | 0.21 |
| 2024-06-30 | 0.18 | 0.20 | 0.16 | 0.07 | 0.17 |
| 2024-03-31 | 0.14 | 0.16 | 0.13 | 0.15 | 0.23 |
| 2023-12-31 | 0.14 | 0.16 | 0.13 | 0.12 | 0.19 |
| 2023-09-30 | 0.17 | 0.19 | 0.16 | 0.04 | 0.20 |
| 2023-06-30 | 0.19 | 0.22 | 0.16 | 0.04 | 0.20 |
| 2023-03-31 | 0.22 | 0.24 | 0.19 | 0.11 | 0.23 |
| 2022-12-31 | 0.24 | 0.27 | 0.21 | 0.06 | 0.14 |
| 2022-09-30 | 0.17 | 0.19 | 0.21 | 0.06 | 0.14 |
| 2022-06-30 | 0.11 | 0.12 | 0.16 | 0.01 | 0.09 |
| 2022-03-31 | 0.14 | 0.15 | 0.10 | 0.05 | 0.07 |
| 2021-12-31 | 0.14 | 0.15 | 0.13 | 0.08 | 0.05 |
| 2021-09-30 | 0.13 | 0.14 | 0.13 | -0.01 | 0.28 |
| 2021-06-30 | 0.12 | 0.14 | 0.12 | 0.14 | 0.28 |
| 2021-03-31 | 0.36 | 0.39 | 0.27 | 0.11 | 0.28 |
| 2020-12-31 | 0.31 | 0.34 | 0.24 | 0.19 | 0.33 |
| 2020-09-30 | 0.42 | 0.45 | 0.30 | 0.23 | 0.39 |
Gross Margins
- marjin kotor untuk Genmab A/S - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.95.
- marjin bersih untuk Genmab A/S - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.35.
- marjin operasi untuk Genmab A/S - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.34.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
| Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
| 2025-06-30 | 0.95 | 0.35 | 0.34 |
| 2025-03-31 | 0.95 | 0.36 | 0.33 |
| 2024-12-31 | 0.96 | 0.24 | 0.33 |
| 2024-09-30 | 0.97 | 0.29 | 0.33 |
| 2024-06-30 | 0.98 | 0.31 | 0.32 |
| 2024-03-31 | 0.99 | 0.26 | 0.32 |
| 2023-12-31 | 0.99 | 0.25 | 0.37 |
| 2023-09-30 | 1.00 | 0.29 | 0.40 |
| 2023-06-30 | 1.00 | 0.29 | 0.40 |
| 2023-03-31 | 1.00 | 0.34 | 0.41 |
| 2022-12-31 | 1.00 | 0.47 | 0.00 |
| 2022-09-30 | 1.00 | 0.47 | 0.38 |
| 2022-06-30 | 1.00 | 0.39 | 0.34 |
| 2022-03-31 | 1.00 | 0.26 | 0.33 |
| 2021-12-31 | 1.00 | 0.35 | 0.36 |
| 2021-09-30 | 1.00 | 0.36 | 0.39 |
| 2021-06-30 | 1.00 | 0.34 | 0.42 |
| 2021-03-31 | 1.00 | 0.52 | 0.63 |
| 2020-12-31 | 1.00 | 0.47 | 0.63 |
| 2020-09-30 | 1.00 | 0.51 | 0.69 |
Pengenal dan Deskriptor
| Kunci Indeks Pusat (CIK) | 1434265 |
Grupong Pang-industriya
| SIC 2834 - Pharmaceutical Preparations |
